Understanding Chronic Kidney Disease: A Guide for English Patients
Recent Trends in CKD Diagnosis and Management
Over the past several years, English healthcare data indicates a steady rise in the number of people diagnosed with chronic kidney disease (CKD). This increase is linked partly to an ageing population and to better screening for related conditions such as diabetes and hypertension. Primary care networks in England have adopted more proactive use of eGFR (estimated glomerular filtration rate) and ACR (albumin-to-creatinine ratio) testing during routine health checks.
- More patients are identified at an earlier stage (CKD stage 1–3) due to improved access to blood and urine tests.
- NHS England has promoted a “kidney health” module in the NHS Health Check for adults aged 40–74.
- Remote monitoring for people with later-stage CKD became more common after the pandemic.
Background of CKD in the English Healthcare System
Chronic kidney disease describes a gradual loss of kidney function over months or years. In England, the condition is managed primarily through general practice, with referral to renal specialists once eGFR falls below 30 ml/min or if there is rapid decline or significant proteinuria. The NHS has published clinical guidelines—most recently from NICE—that recommend standardised staging and treatment targets.
- CKD is five times more common in people of South Asian, Black African, and Black Caribbean heritage in England.
- Diabetes and high blood pressure account for roughly two-thirds of all CKD cases.
- The NHS Long Term Plan included commitments to increase home dialysis and transplant rates.
Common Patient Concerns
Patients in England often worry about whether CKD will inevitably progress to kidney failure, how diet needs to change, and whether they will need dialysis or a transplant. Fear of side effects from medications (such as ACE inhibitors or SGLT2 inhibitors) and uncertainty about the meaning of eGFR numbers also feature prominently.
- Many patients misunderstand that stage 1–2 CKD usually requires only monitoring and lifestyle changes, not aggressive treatment.
- Concern about dietary restrictions (reducing salt, potassium, and phosphate) can cause anxiety, especially when advice seems contradictory.
- Waiting times for specialist appointments vary across trusts, raising worries about access for remote or rural patients.
Likely Impact of Policy and Treatment Changes
Recent NICE guideline updates recommend wider use of SGLT2 inhibitors (like dapagliflozin) for patients with CKD and albuminuria, regardless of diabetes status. This is expected to slow progression for tens of thousands of English patients. At the same time, NHS England’s focus on “prevention” is likely to increase case-finding in primary care, potentially raising the number of diagnosed cases while hopefully reducing late-stage presentations.
- More people may be prescribed SGLT2 inhibitors, with careful monitoring of eGFR and potassium.
- Home haemodialysis and peritoneal dialysis capacity is being expanded, which could reduce hospital-based burden and improve quality of life.
- Greater awareness of CKD among GPs may reduce variation in referral times across regions.
What to Watch Next
Key developments to follow in the English CKD landscape include the rollout of the NHS Kidney Care dashboard (to track outcomes at practice level) and pending NICE reviews of newer therapies such as finerenone and tirzepatide for CKD in diabetes. The National Renal Dataset will also be updated, which may influence how performance is measured and funded.
- Watch for national audit reports on the percentage of CKD patients on optimal RAAS blockade and SGLT2 therapy.
- Monitor any changes to the NHS Health Check protocol regarding urinary ACR testing in non-diabetic populations.
- Observe how the planned transition to integrated care systems (ICS) improves—or complicates—patient access to renal dietitians and nursing support.